Hrt Financial LP Avadel Pharmaceuticals PLC Transaction History

Hrt Financial LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$7.34 - $11.18 $100,763 - $153,479	-13,728 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.49 - $9.91 $275,000 - $419,916	-42,373 Reduced 75.53%	13,728 $134,000
Q2 2021 Aug 16, 2021	BUY	$6.73 - $9.05 $286,570 - $385,358	42,581 Added 314.95%	56,101 $377,000
Q1 2021 May 17, 2021	BUY	$6.61 - $10.07 $89,367 - $136,146	13,520 New	13,520 $122,000
Q4 2020 Feb 16, 2021	SELL	$5.03 - $7.95 $59,540 - $94,104	-11,837 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$5.02 - $8.98 $4,292 - $7,677	-855 Reduced 6.74%	11,837 $59,000
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $92,017 - $149,131	12,692 New	12,692 $102,000
Q1 2019 May 14, 2019	SELL	$1.44 - $3.29 $18,970 - $43,342	-13,174 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$1.74 - $4.66 $22,922 - $61,390	13,174 New	13,174 $33,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.